Skip to content

A Study to Test the Safety and Effectiveness of a Unani Medicine for Bronchial Asthma

A Clinical Study On Zeeq-Un-Nafas (Bronchial Asthma) To Evaluate the Safety And Efficacy Of a Unani Polyherbal Formulation In Its Management-An Open-Label Single Arm Trial - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/04/085788
Enrollment
35
Registered
2025-04-28
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

Intervention1: Decoction of a Unani Polyherbal Formulation: Decoction prepared in water of the following drugs will be given orally once a day before breakfast for 45 days. Tukhm Katan (Linum usitatis

Sponsors

Ayurvedic and Unani Tibbia College and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Clinically diagnosed cases of bronchial asthma. Patient between 18 and 60 years of age. Patient of either sex. Mild to moderate persistent asthma cases. Patient willing to participate in the study.

Exclusion criteria

Exclusion criteria: Patients below the age of 18 and above 60 years of age . Patients having Chronic obstructive pulmonary disease (COPD),Pulmonary tuberculosis, Pneumonia, Occupational lung disease ,Lung carcinoma and other respiratory diseases. Patients having diabetes mellitus, hypertension, cardiovascular disease, impaired renal function, impaired liver function and other malignancies. Severe Exacerbation (FEV1 or PEF less than 50 percent predicted) or asthma related intubation. Pregnant or lactating women. Patients who had received corticosteroids, bronchodilators or CAM therapy within 2 weeks prior to enrollment. Patients on other therapies (allopathic, homeopathic or other drugs) along with our trial drug. Patients who refuse to give written consent for the study.

Design outcomes

Primary

MeasureTime frame
1.Improvement in the subjective parameters such as cough, sputum, dyspnea, wheezing and crepitations in response to the treatment. 2.Improvement in FEV1,PEF,FEV1/FVC ratio in response to the treatment.Timepoint: 1.Assessment of the subjective parameters at baseline, 15th, 30th and 45th day. 2.Assessment of the objective parameters at baseline and 45th day.

Secondary

MeasureTime frame
1.Improvement in ACT score in response to the treatment. 2.Improvement in the Quality of life in response to the treatment.Timepoint: 1.Assessment of ACT score at baseline,15th 30th and 45th day. 2.Assessment of the Quality of life at baseline and 45th day.

Countries

India

Contacts

Public ContactSyed Aabid Hasan

Ayurvedic and Unani Tibbia College and Hospital, Karol Bagh, New Delhi

drkhannaseem.akhtarkhan@gmail.com9810815997

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026